AbbVie Inc., a mega-cap pharmaceutical company with a market cap of $371.7 billion, specializes in immunology, oncology, aesthetics, neuroscience, and eye care. Despite a recent dip from its 52-week high, ABBV stock has outperformed the S&P 500 Index in the past three months, with a 13.4% gain.

Shares of ABBV have risen 18.4% year-to-date but only 7.7% over the past 52 weeks, indicating strong performance in the short term. The stock has been trading above its moving averages since June, signaling a bullish trend.

While ABBV beat Q2 earnings expectations, challenges loom with declining Humira sales and slower market growth for Juvederm fillers. Despite this, revenue rose 6.6% year-over-year to $15.4 billion, and adjusted EPS increased 12.1% to $2.97. The company raised its fiscal 2025 adjusted EPS guidance to $11.88-$12.08.

Compared to Eli Lilly and Company, ABBV has performed better, with a consensus “Moderate Buy” rating and a mean price target of $215.81, suggesting a potential upside of 2.6% from current levels. Analysts are reasonably bullish on ABBV’s prospects, despite challenges faced by the company.

Read more at Yahoo Finance: Is AbbVie Stock Underperforming the S&P 500?